CN104039353A - 增强认知的方法 - Google Patents

增强认知的方法 Download PDF

Info

Publication number
CN104039353A
CN104039353A CN201280058641.1A CN201280058641A CN104039353A CN 104039353 A CN104039353 A CN 104039353A CN 201280058641 A CN201280058641 A CN 201280058641A CN 104039353 A CN104039353 A CN 104039353A
Authority
CN
China
Prior art keywords
pkr
mice
slices
term
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280058641.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·科斯塔-马提欧利
P·J·朱
J·A·梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
University of Houston
Original Assignee
Baylor College of Medicine
University of Houston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, University of Houston filed Critical Baylor College of Medicine
Publication of CN104039353A publication Critical patent/CN104039353A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280058641.1A 2011-11-29 2012-11-29 增强认知的方法 Pending CN104039353A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161564371P 2011-11-29 2011-11-29
US61/564,371 2011-11-29
PCT/US2012/067078 WO2013082292A1 (en) 2011-11-29 2012-11-29 A method to enhance cognition

Publications (1)

Publication Number Publication Date
CN104039353A true CN104039353A (zh) 2014-09-10

Family

ID=48536059

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280058641.1A Pending CN104039353A (zh) 2011-11-29 2012-11-29 增强认知的方法

Country Status (8)

Country Link
US (1) US20140336184A1 (https=)
EP (1) EP2785377A4 (https=)
JP (1) JP2015500805A (https=)
CN (1) CN104039353A (https=)
AU (1) AU2012345888A1 (https=)
CA (1) CA2856424A1 (https=)
HK (1) HK1200085A1 (https=)
WO (1) WO2013082292A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107969126A (zh) * 2015-06-26 2018-04-27 埃克西金炎症有限公司 Jnk信号转导通路的细胞穿透肽抑制剂用于治疗轻度认知损害的新用途
CN108697889A (zh) * 2015-11-24 2018-10-23 麻省理工学院 用于预防、减轻和/或治疗痴呆的系统和方法
US12311194B2 (en) 2017-10-10 2025-05-27 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia
US12383759B2 (en) 2016-11-17 2025-08-12 Cognito Therapeutics, Inc. Methods and systems for neural stimulation via visual, auditory and peripheral nerve stimulations
US12515069B2 (en) 2017-10-10 2026-01-06 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110052566A1 (en) * 2008-12-23 2011-03-03 Carmel-Haifa University Economic Corp., Ltd. Cognitive function

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
AU2003272539A1 (en) * 2002-09-17 2004-04-08 New York University Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
DE112005001269T5 (de) * 2005-04-26 2008-05-29 Versitech Ltd. Polysaccharidextrakt aus Lycium barbarum als neuroprotektives Mittel gegen ß-Amyloidpeptidneurotoxizität
CA2706656A1 (en) * 2007-11-26 2009-06-04 Nestec S.A. Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition
CA2774266A1 (en) * 2009-09-16 2011-03-24 Cylene Pharmaceuticals, Inc. Novel tricyclic protein kinase modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110052566A1 (en) * 2008-12-23 2011-03-03 Carmel-Haifa University Economic Corp., Ltd. Cognitive function

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107969126A (zh) * 2015-06-26 2018-04-27 埃克西金炎症有限公司 Jnk信号转导通路的细胞穿透肽抑制剂用于治疗轻度认知损害的新用途
CN108697889A (zh) * 2015-11-24 2018-10-23 麻省理工学院 用于预防、减轻和/或治疗痴呆的系统和方法
US12296106B2 (en) 2015-11-24 2025-05-13 Massachusetts Institute Of Technology Methods and devices for providing a stimulus to a subject to induce gamma oscillations
US12318549B2 (en) 2015-11-24 2025-06-03 Massachusetts Institute Of Technology Methods and devices for providing a stimulus to a subject to induce gamma oscillations
US12383759B2 (en) 2016-11-17 2025-08-12 Cognito Therapeutics, Inc. Methods and systems for neural stimulation via visual, auditory and peripheral nerve stimulations
US12434072B2 (en) 2016-11-17 2025-10-07 Cognito Therapeutics, Inc. Methods and systems for neural stimulation via visual, auditory and peripheral nerve stimulations
US12311194B2 (en) 2017-10-10 2025-05-27 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia
US12515069B2 (en) 2017-10-10 2026-01-06 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function

Also Published As

Publication number Publication date
JP2015500805A (ja) 2015-01-08
HK1200085A1 (en) 2015-07-31
WO2013082292A1 (en) 2013-06-06
EP2785377A4 (en) 2015-07-08
EP2785377A1 (en) 2014-10-08
AU2012345888A1 (en) 2014-05-29
US20140336184A1 (en) 2014-11-13
CA2856424A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
KR102836833B1 (ko) 신규 메틸퀴나졸리논 유도체
KR102614808B1 (ko) Nash/nafld 및 관련 질환의 치료를 위한 조합물
KR20210005222A (ko) Rip1 억제 화합물 및 이를 제조하고 사용하는 방법
CN111065393B (zh) 用于治疗皮肤疾病的吡咯并吡啶-苯胺类化合物
CN110478353B (zh) 治疗和预防同种抗体驱动的慢性移植物抗宿主病的方法
UA128160C2 (uk) Сполуки, що інгібують rip1, а також способи їх одержання та застосування
JP2019511495A (ja) ＧＳＫ３β阻害薬チデグルシブによるＣＤＫＬ５障害の治療
KR20120104200A (ko) Ｃｎｓ 장애의 치료를 위한 8­에틸­6­(아릴）피리도［2,3­ｄ］피리미딘­7（8ｈ）­온
CN104039353A (zh) 增强认知的方法
SK154796A3 (en) Use of rapamycin for the inhibition of neuronal cells necrosis
US11746089B2 (en) Compounds and methods for treating alcohol disorder
JP2026048839A (ja) 治療方法
CA3251930A1 (en) TREATMENT OF DISEASES AND DISORDERS WITH MIRACLES MODIFYING COMPOUNDS 4
CN104230742B (zh) 萘衍生物及其在药物上的应用
JP2007506784A (ja) 双極性障害およびその他の認知障害の治療における、ケレリトリン、その類似体およびそれらの使用
US20250017878A1 (en) Use of nadolol to treat chronic obstructive pulmonary disease by blockage of the arrestin-2 pathway
US12472180B2 (en) Combinations for treatment of NAFLD/NASH and related diseases
US12371450B2 (en) Carbalysophosphatidic acid
US20220362177A1 (en) Ceramide ratios as predictive and therapeutic biomarkers for leukemias
EP4284381A1 (en) Methods for the treatment of childhood-onset fluency disorder
RU2802968C1 (ru) Новые производные метилхиназолинона
US20250388571A1 (en) Amp-activated protein kinase modulator compounds and uses thereof
CA3162883C (en) (3r)-and (3s)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide compounds and their use as braf inhibitors
EP3630093B1 (en) Treatment of diseases associated with a dysregulation of the mtor pathway
HK1174920A (en) 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140910

WD01 Invention patent application deemed withdrawn after publication